Literature DB >> 25659455

Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis.

Michael Czihal1, Anne Piller2, Angelika Schroettle2, Peter Kuhlencordt2, Christoph Bernau3, Hendrik Schulze-Koops4, Ulrich Hoffmann2.   

Abstract

OBJECTIVE: Color duplex sonography (CDS) today is broadly used in the diagnostic workup of patients with suspected cranial or extracranial giant cell arteritis (GCA). This study aimed to determine the prognostic impact of the disease pattern assessed by CDS on the treatment response in GCA.
METHODS: This was a retrospective, longitudinal follow-up study of 43 patients who were diagnosed with GCA at our institution between 2002 and 2010. All patients underwent CDS of the temporal and subclavian/axillary arteries at baseline and were observed for at least 6 months. Vasculitis was sonographically characterized by a circumferential, hypoechogenic wall thickening. According to the CDS findings, patients were categorized into patients with involvement of the subclavian/axillary arteries only (group A1, n = 17), patients with involvement of both the subclavian/axillary arteries and the temporal arteries (group A2, n = 9), and patients with isolated cranial GCA (group B, n = 17). Data on recurrences, corticosteroid doses, and steroid-sparing agents were extracted from the medical records. Treatment response over time was analyzed by Kaplan-Meier curves with log-rank testing.
RESULTS: The mean follow-up time was 25.4 months and did not differ between groups (P = .4). Patients in group A1 were significantly younger than patients in groups A2 and B (P < .01). The interval between symptom onset and diagnosis was significantly longer in groups A1 and A2 compared with group B (P < .01). The number of recurrences per month was significantly higher in group A2 compared with group A1 and group B (A1, 0.07; A2, 0.13; B, 0.03; P < .01). Whereas there were no significant differences in the mean time until a daily prednisolone dose <10 mg was reached, patients in group A2 more frequently required steroid-sparing agents (A1, 24%; A2, 56%; B, 24%; P = .04).
CONCLUSIONS: Extensive vascular involvement of both the temporal and subclavian/axillary arteries, as depicted by CDS, may be associated with a poor treatment response in GCA.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25659455     DOI: 10.1016/j.jvs.2014.12.045

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  12 in total

Review 1.  The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist.

Authors:  Sara Monti; Alberto Floris; Cristina Ponte; Wolfgang A Schmidt; Andreas P Diamantopoulos; Claudio Pereira; Jennifer Piper; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

Review 2.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Authors:  Alvise Berti; Roberto Caporali; Carlomaurizio Montecucco; Giuseppe Paolazzi; Sara Monti
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 3.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

Review 4.  Imaging in Giant Cell Arteritis.

Authors:  Asad Khan; Bhaskar Dasgupta
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

5.  Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA).

Authors:  Alwin Sebastian; Kornelis S M van der Geest; Fiona Coath; Prisca Gondo; Abdul Kayani; Craig Mackerness; Bernard Hadebe; Sue Innes; Jo Jackson; Bhaskar Dasgupta
Journal:  BMC Rheumatol       Date:  2020-08-18

6.  Associations among temporal and large artery abnormalities on vascular ultrasound in giant cell arteritis.

Authors:  M A DiIorio; P S Sobiesczcyk; C Xu; W Huang; J A Ford; S S Zhao; D H Solomon; W P Docken; S K Tedeschi
Journal:  Scand J Rheumatol       Date:  2021-03-03       Impact factor: 3.057

Review 7.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

8.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Authors:  Sara Monti; Ana F Águeda; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-16

9.  Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.

Authors:  Takahiko Sugihara; Hitoshi Hasegawa; Haruhito A Uchida; Hajime Yoshifuji; Yoshiko Watanabe; Eisuke Amiya; Yasuhiro Maejima; Masanori Konishi; Yohko Murakawa; Noriyoshi Ogawa; Shunsuke Furuta; Yasuhiro Katsumata; Yoshinori Komagata; Taio Naniwa; Takahiro Okazaki; Yoshiya Tanaka; Tsutomu Takeuchi; Yoshikazu Nakaoka; Yoshihiro Arimura; Masayoshi Harigai; Mitsuaki Isobe
Journal:  Arthritis Res Ther       Date:  2020-04-07       Impact factor: 5.156

Review 10.  Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides.

Authors:  Valentin Sebastian Schäfer; Lei Jin; Wolfgang Andreas Schmidt
Journal:  Curr Rheumatol Rep       Date:  2020-09-21       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.